Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Investor Presentation
We are forwarding a copy of Presentation on Quarterly Results of our company for the quarter / nine months ended 31-12-2020. Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised. Thyrocare Technologies Ltd - 539871 - Results- Unaudited Financial Results (Standalone And Consolidated) For The Quarter / Nine Months Ended 31-12-2020
This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Nine Month Period ended December 31, 2020. The said unaudited financial results, along with the Limited Review Reports, are attached pursuant to Regulation 33 (3) (a) to (c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board decided to defer the question of further dividend to the next meeting. With regard to appointment of new auditors, the Board authorized Dr. A. Velumani, Chairman & Managing Director, Mr. A. Sundararaju, Executive Director & CFO and Mr. G.S. Hegde, Independent Director, to take a decision and report to the Committee / Board at the earliest. This is to inform that the meeting commenced at 17.30 hours and ended at 20.25 hours today, the 30th January, 2021. Thyrocare Technologies Ltd - 539871 - Outcome Of Board Meeting
This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Nine Month Period ended December 31, 2020. The said unaudited financial results, along with the Limited Review Reports, are attached pursuant to Regulation 33 (3) (a) to (c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board decided to defer the question of further dividend to the next meeting. With regard to appointment of new auditors, the Board authorized Dr. A. Velumani, Chairman & Managing Director, Mr. A. Sundararaju, Executive Director & CFO and Mr. G.S. Hegde, Independent Director, to take a decision and report to the Committee / Board at the earliest. This is to inform that the meeting commenced at 17.30 hours and ended at 20.25 hours today, the 30th January, 2021. Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for To Consider & Approve Unaudited Financial Results For Quarter Ended 31-12-2020, To Consider & Decide On Payment Of Interim Dividend, If Any, And To Consider Appointment Of New Auditors In The Place Of Current Auditors Whose Term Would Expire Shortly.
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Saturday, January 30, 2021, to inter alia, consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter / nine months ended December 31, 2020, to consider and decide on payment of 2nd Interim Dividend, if any, for the financial year 2020-21 and to decide on the appointment of new Auditors in the place of present Auditors (whose consecutive term of ten years would come to an end as at the conclusion of ensuing Annual General Meeting), subject to approval of the Members at the general meeting. Intimation of the above meeting of the Board of Directors is also being published in newspapers, as required under Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Business Today MindRush 2021: Top corporate honchos to discuss state of economy, the way ahead
Business Today MindRush 2021: Bharat Biotech's CMD Krishna Ella will discuss the future of healthcare post-COVID with Thyrocare MD A Velumani and Public Health Foundation of India President Srinath Reddy on day one of the event Thyrocare Technologies Ltd - 539871 - Shareholding for the Period Ended December 31, 2020
Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here Thyrocare Technologies Ltd - 539871 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to the provisions of Regulation 74 (5) of the Security and Exchange Board of India (Depositories and Participants) Regulations, 2018, we are forwarding herewith a copy of certificate dated 13th January, 2021 issued by our Registrar and Share Transfer Agent, Link Intime India Private Limited, for the quarter ended December 31, 2020. This is for your information and records. Thyrocare Technologies Ltd - 539871 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ramjee DoraiDesignation :- Company Secretary and Compliance Officer Testing recovery gains factored in Thyrocare Technologies stock
Margin pressures and valuations would limit major upsides Thyrocare Technologies Ltd - Business Update
Intimation about (1) significant business revival in Q3 of the current financial year, after business activities resumed across all states, and the growth in the non-covid business and (2) increase in volume of RT-PCR tests making us most cost effective service provider to the patients.